Know Cancer

forgot password

Analysis of Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer

45 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

Analysis of Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer

Inclusion Criteria:

- Postmenopausal patients, defined as one or more of the following criteria:

Documented history of bilateral oophorectomy, Aged 60 years or more,

Aged 45-59 years and satisfying one or more of the following criteria:

Amenorrhea for at least 12 months and intact uterus Amenorrhea for less than 12 months and
follicle stimulating hormone (FSH) concentrations within postmenopausal range including:
patients who have had a hysterectomy and patients who have received hormone replacement
therapy in the past.

- Clinically palpable or non-palpable T1c or greater, ER positive invasive breast
cancer diagnosed by outside core biopsy.

- Outside diagnosis of invasive breast cancer confirmed at MSKCC

- Palpable or non-palpable breast mass > 1cm highly suspicious for invasive breast
cancer based on mammographic, ultrasound and/or physical examination findings and
amenable to diagnostic core biopsy.

- Core biopsy diagnosis of ER positive invasive breast cancer performed at MSKCC

- Breast conserving surgery or mastectomy scheduled at MSKCC.

- Informed consent obtained.

Exclusion Criteria:

- Co-morbid conditions which would preclude use of aromatase inhibitors such as:
previous hypersensitivity, severe hepatic insufficiency (SGOT or SGPT three times the
upper limit of normal), severe renal insufficiency (creatinine clearance <10ml/min).

Prior radiation therapy to chest wall / breast.

- Neoadjuvant chemotherapy

- Hormone replacement therapy, tamoxifen or raloxifene treatment within past 3 months

- ER negative breast cancer

- History of active malignancy within the previous 5 years (except for nonmelanoma skin
cancer and breast cancer)

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine whether short term exposure to endocrine therapy (anastrozole) induces changes in gene expression in human invasive breast cancer.

Outcome Time Frame:

conclusion of study

Safety Issue:


Principal Investigator

Tari King, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

March 2004

Completion Date:

November 2009

Related Keywords:

  • Breast Cancer
  • Breast
  • Breast Neoplasms



Memorial Sloan-Kettering Cancer CenterNew York, New York  10021